Editas Medicine Inc (EDIT)
2.44
+0.07
(+2.95%)
USD |
NASDAQ |
Nov 22, 16:00
2.435
0.00 (0.00%)
After-Hours: 20:00
Editas Medicine Cash from Financing (Quarterly): 0.00 for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.322M |
| March 31, 2024 | 0.192M |
| December 31, 2023 | 0.514M |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 117.52M |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.619M |
| September 30, 2022 | 0.08M |
| June 30, 2022 | 0.367M |
| March 31, 2022 | 0.218M |
| December 31, 2021 | 1.057M |
| September 30, 2021 | 2.496M |
| June 30, 2021 | 17.08M |
| March 31, 2021 | 261.47M |
| December 31, 2020 | 9.10M |
| September 30, 2020 | 0.822M |
| June 30, 2020 | 211.15M |
| March 31, 2020 | 3.047M |
| December 31, 2019 | 84.57M |
| Date | Value |
|---|---|
| September 30, 2019 | 43.35M |
| June 30, 2019 | 2.369M |
| March 31, 2019 | 1.533M |
| December 31, 2018 | 30.35M |
| September 30, 2018 | 1.24M |
| June 30, 2018 | 2.667M |
| March 31, 2018 | 52.68M |
| December 31, 2017 | 58.48M |
| September 30, 2017 | -0.73M |
| June 30, 2017 | -0.309M |
| March 31, 2017 | 97.09M |
| December 31, 2016 | -0.538M |
| September 30, 2016 | -0.022M |
| June 30, 2016 | -0.494M |
| March 31, 2016 | 98.22M |
| December 31, 2015 | -3.752M |
| September 30, 2015 | 120.39M |
| June 30, 2015 | 21.96M |
| March 31, 2015 | 0.791M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
--
Minimum
Mar 2023
261.47M
Maximum
Mar 2021
35.53M
Average
0.7205M
Median
Cash from Financing (Quarterly) Benchmarks
| Ionis Pharmaceuticals Inc | 496.05M |
| EyePoint Pharmaceuticals Inc | 11.89M |
| Cassava Sciences Inc | 0.00 |
| Adverum Biotechnologies Inc | 0.00 |
| Regenxbio Inc | -10.86M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -52.59M |
| Cash from Investing (Quarterly) | 83.98M |
| Free Cash Flow | -191.36M |
| Free Cash Flow Per Share (Quarterly) | -0.673 |
| Free Cash Flow to Equity (Quarterly) | -55.51M |
| Free Cash Flow Yield | -95.49% |